(-0.14%) 5 461.42 points
(-0.33%) 38 981 points
(0.21%) 17 755 points
(-0.05%) $80.79
(-3.48%) $2.66
(-1.00%) $2 307.50
(-0.46%) $28.74
(1.26%) $998.80
(0.25%) $0.936
(0.88%) $10.70
(0.36%) $0.791
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases...
Stats | |
---|---|
本日の出来高 | 31 451 |
平均出来高 | 1.62M |
時価総額 | 61.14M |
EPS | $-0.470 ( Q1 | 2024-05-09 ) |
次の収益日 | ( $-0.420 ) 2024-08-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.780 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00800 (0.54%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-15 | Hunt Ronald | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Boudreau Helen M | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Liu Hui | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Parmar Kush | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Soteropoulos Paula | Buy | 16 500 | Option (Right to Buy) |
INSIDER POWER |
---|
92.07 |
Last 96 transactions |
Buy: 8 046 287 | Sell: 10 802 620 |
ボリューム 相関
Rallybio Corporation 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Rallybio Corporation 相関 - 通貨/商品
Rallybio Corporation 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-150 000 (0.00 %) |
EPS: | $-1.840 |
FY | 2023 |
収益: | $0 |
総利益: | $-150 000 (0.00 %) |
EPS: | $-1.840 |
FY | 2022 |
収益: | $0 |
総利益: | $-167 000 (0.00 %) |
EPS: | $-2.09 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.653 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。